efmoroctocog alfa
SpainDrugs containing this active substance
-
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 133,3 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 200 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 266,7 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 33,3 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 400 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 4000 UI Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 66,7 µg Manufacturer: Swedish Orphan Biovitrum Ab (Publ)
-
It is used to treat and prevent bleeding in patients of any age with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 750 UI Manufacturer: Swedish Orphan Biovitrum Ab (Publ)